Small Pharma Inc. is a biotechnology firm focused on developing fast-acting psychedelic therapies, coupled with supportive psychological care, to address mental health conditions. Its flagship clinical initiative centers on N,N-dimethyltryptamine (DMT) assisted therapy designed to combat major depressive disorder. Specifically, its compound SPL026 is currently in Phase IIA clinical trials for MDD treatment.